Home > Boards > US Listed > Biotechs > Ruthigen, Inc. (RTGN)

Company now Pulmatrix We design and develop inhaled therapeutic

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
RealGenius Member Profile
Member Level 
Followed By 88
Posts 1,965
Boards Moderated 0
Alias Born 07/31/13
160x600 placeholder
RealGenius Member Level  Wednesday, 06/17/15 12:44:18 AM
Re: None
Post # of 107 
Company now Pulmatrix
We design and develop inhaled therapeutic products based on our proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. We are developing iSPERSE-based therapeutic candidates targeted at prevention and treatment of a range of respiratory diseases, targeting chronic obstructive pulmonary disease (COPD) and rare/orphan indications including cystic fibrosis (CF), and idiopathic pulmonary fibrosis (IPF).

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences